5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients

Psychiatry Research

Volumn 167, Issue 1-2, 2009, Pages 97-105

  Kato, Masaki ^a,b   Zanardi, Raffaella ^c   Rossini, David ^c   De Ronchi, Diana ^a   Okugawa, Gaku ^b   Kinoshita, Toshihiko ^b   Colombo, Cristina ^c   Serretti, Alessandro ^a,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b KANSAI MEDICAL UNIVERSITY   (Japan)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

5 HT2A; Depression; Pharmacogenetics; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; FLUVOXAMINE; PAROXETINE; SEROTONIN 2A RECEPTOR;

5 HT2A GENE; ADULT; ARTICLE; DNA DETERMINATION; ETHNICITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HETEROZYGOTE; HUMAN; ITALY; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; POPULATION RESEARCH; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RACE DIFFERENCE; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUVOXAMINE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; PAROXETINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 64649085663     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2007.12.012     Document Type: Article

References (56)

1. Aghajanian G.K., and Sanders-Bush E. Serotonin. In: Davis K.L., Charney D., Coyle J.T., and Nemeroff C. (Eds). Neuropsychopharmacology: The Fifth Generation of Progress (2002), Lippincott Williams & Wilkins, Philadelphia 15-34
2. Bech P., Malt U., Dencker S., Ahlfors U., Elgen K., Lewander T., Lundell A., Simpson G., and Lingjaerde O. Scales for assessment of diagnosis and severity of mental disorders. Acta Psychiatrica Scandinavica 87 Suppl 372 (1993) 37-40
3. Bray N.J., Buckland P.R., Hall H., Owen M.J., and O'Donovan M.C. The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Molecular Psychiatry 9 (2004) 109-114
4. Cavalli Sforza L. The History and Geography of Human Genes (1994), Princeton University Press, Princeton, New Jersey, USA
5. Choi M.J., Kang R.H., Ham B.J., Jeong H.Y., and Lee M.S. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 52 (2005) 155-162
6. Cloninger C. Turning point in the design of linkage studies of schizophrenia. American Journal of Medical Genetics 54 (1994) 83-92
7. Cloninger C., Adolfsson R., and Svrakic N. Mapping genes for human personality. Nature Genetics 12 (1996) 3-4
8. Cohen J. Statistical Power Analysis for the Behavioral Sciences (1988), Lawrence Erlbaum Associates, Hillsdale, New Jersey 8-14
9. Comings D. Polygenic inheritance in psychiatric disorders. In: Blum K., and Noble E.P. (Eds). Handbook of Psychiatric Genetics (1997), CRC Press, Boca Raton, FL 235-260
10. Cusin C., Serretti A., Zanardi R., Lattuada E., Rossini D., Lilli R., Lorenzi C., and Smeraldi E. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRIs antidepressant activity. International Journal of Neuropsychopharmacology 5 (2002) 27-35
11. First M.B., Spitzer R.L., Gibbon M., and Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New York (1995)
12. Ginsburg B., Werick T., Escobar J., and Kugelmass S. Moleculargenetics of psychopathologies: a search for simple answers to complex problems. Behavior Genetics 26 (1996) 325-333
13. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 6 (1967) 278-296
14. Hong C.J., Chen T.J., Yu Y.W., and Tsai S.J. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics Journal 6 (2006) 27-33
15. International HapMap Project. Nature 426 (2003) 789-796
16. Jakab R.L., and Goldman-Rakic P.S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proceedings of the National Academy of Sciences of the USA 95 (1998) 735-740
17. Kato M., Fukuda T., Wakeno M., Fukuda K., Okugawa G., Ikenaga Y., Yamashita M., Takekita Y., Nobuhara K., Azuma J., and Kinoshita T. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53 (2006) 186-195
18. Kendler K.S. "A gene for...": the nature of gene action in psychiatric disorders. American Journal of Psychiatry 162 (2005) 1243-1252
19. Kirmayer L.J. Cultural variations in the clinical presentation of depression and anxiety: implications for diagnosis and treatment. Journal of Clinical Psychiatry 62 Suppl 13 (2001) 22-28 discussion 29-30
20. Koenig H.G., George L.K., and Peterson B.L. Religiosity and remission of depression in medically ill older patients. American Journal of Psychiatry 155 (1998) 536-542
21. Kunugi H., Hattori M., Kato T., Tatsumi M., Sakai T., Sasaki T., Hirose T., and Nanko S. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Molecular Psychiatry 2 (1997) 457-462
22. Lahiri D.K., and Nurnberger J.I.J. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acid Research 19 (1991) 5444
23. Lattuada E., Serretti A., Cusin C., Gasperini M., Macciardi F., and Smeraldi E. Symptomatologic analysis of psychotic and non-psychotic depression. Journal of Affective Disorders 54 (1999) 183-187
24. Lopez-Gimenez J.F., Mengod G., Palacios J.M., and Vilaro M.T. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. Naunyn-Schmiedebergs Archives of Pharmacology 356 (1997) 446-454
25. Maj J., Bijak M., Dziedzicka-Wasylewska M., Rogoz R., Rogoz Z., Skuza G., and Tokarski T. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology (Berl) 127 (1996) 73-82
26. McMahon F.J., Buervenich S., Charney D., Lipsky R., Rush A.J., Wilson A.F., Sorant A.J.M., Papanicolaou G.J., Laje G., Fava M., Trivedi M.H., Wisniewski S.R., and Manji H. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78 (2006) 804-814
27. Meyer J.H., Kapur S., Eisfeld B., Brown G.M., Houle S., DaSilva J., Wilson A.A., Rafi-Tari S., Mayberg H.S., and Kennedy S.H. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. American Journal of Psychiatry 158 (2001) 78-85
28. Minov C., Baghai T.C., Schule C., Zwanzger P., Schwarz M.J., Zill P., Rupprecht R., and Bondy B. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neuroscience Letters 303 (2001) 119-122
29. Miyamoto S., Duncan G.E., Goff D.C., and Lieberman J.A. Therapeutics of schizophrenia. In: Davis K.L., Charney D., Coyle J.T., and Nemeroff C. (Eds). Neuropsychopharmacology: the Fifth Generation of Progress (2002), Lippincott Williams & Wilkins, Philadelphia 775-807
30. Murphy Jr. G.M., Kremer C., Rodrigues H.E., and Schatzberg A.F. Pharmacogenetics of antidepressant medication intolerance. American Journal of Psychiatry 160 (2003) 1830-1835
31. Parsons M.J., D'Souza U.M., Arranz M.J., Kerwin R.W., and Makoff A.J. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biological Psychiatry 56 (2004) 406-410
32. Peters E.J., Slager S.L., McGrath P.J., Knowles J.A., and Hamilton S.P. Investigation of serotonin-related genes in antidepressant response. Molecular Psychiatry 9 (2004) 879-889
33. Polesskaya O.O., and Sokolov B.P. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. Journal of Neuroscience Research 67 (2002) 812-822
34. Risch N. Linkage strategies for genetically complex traits: I. Multilocus models. American Journal of Medical Genetics 46 (1990) 222-228
35. *D report. American Journal of Psychiatry 163 (2006) 1905-1917
36. Sartorius N. The economic and social burden of depression. Journal of Clinical Psychiatry 62 Suppl 15 (2001) 8-11
37. Sato K., Yoshida K., Takahashi H., Ito K., Kamata M., Higuchi H., Shimizu T., Itoh K., Inoue K., Tezuka T., Suzuki T., Ohkubo T., Sugawara K., and Otani K. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 46 (2002) 136-140
38. Serretti A., Lattuada E., Cusin C., Macciardi F., and Smeraldi E. Analysis of depressive symptomatology in mood disorders. Depression and Anxiety 8 (1998) 80-85
39. Serretti A., Jori M.C., Casadei G., Ravizza L., Smeraldi E., and Akiskal H. Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression. Journal of Affective Disorders 56 (1999) 17-25
40. Serretti A., Cusin C., Rossini D., Artioli P., Dotoli D., and Zanardi R. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. American Journal of Medical Genetics 129B (2004) 36-40
41. Serretti A., Artioli P., and Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 15 (2005) 61-67
42. Serretti A., Cusin C., Benedetti F., Mandelli L., Pirovano A., Zanardi R., Colombo C., and Smeraldi E. Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. American Journal of Medical Genetics Part B, Neuropsychiatric Genetics 137 (2005) 36-39
43. Serretti A., Mandelli L., Lorenzi C., Pirovano A., Olgiati P., Colombo C., and Smeraldi E. Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders. Psychiatry Research 149 (2007) 185-193
44. Serretti A., Kato M., De Ronchi D., and Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Molecular Psychiatry 12 (2007) 247-257
45. Serretti A., Calati R., Mandelli L., and De Ronchi D. Serotonin transporter gene variants and behaviour: a comprehensive review. Current Drug Targets 7 (2006) 1659-1669
46. Sobin C.A., and Sackeim H. Psychomotor symptoms of depression. American Journal of Psychiatry 154 (1997) 4-17
47. Spurlock G., Heils A., Holmans P., Williams J., D'Souza U.M., Cardno A., Murphy K.C., Jones L., Buckland P.R., McGuffin P., Lesch K.P., and Owen M.J. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Molecular Psychiatry 3 (1998) 42-49
48. Stanley M., and Mann J.J. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1 (1983) 214-216
49. Suzuki Y., Sawamura K., and Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 31 (2006) 825-831
50. Thase M.E., Haight B.R., Richard N., Rockett C.B., Mitton M., Modell J.G., VanMeter S., Harriett A.E., and Wang Y. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. Journal of Clinical Psychiatry 66 (2005) 974-981
51. Tsuang M., and Faraone S. The Genetics of Mood Disorders (1990), The Johns Hopkins University Press, Baltimore 1-31
52. Ustun T.B. The worldwide burden of depression in the 21st century. In: Weismann M.M. (Ed). Treatment of Depression: Bridging the 21st Century (2001), American Psichiatric Press, Washington, DC 35-45
53. Varnas K., Halldin C., and Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Human Brain Mapping 22 (2004) 246-260
54. Wu C., Yoder E.J., Shih J., Chen K., Dias P., Shi L., Ji X.D., Wei J., Conner J.M., Kumar S., Ellisman M.H., and Singh S.K. Development and characterization of monoclonal antibodies specific to the serotonin 5-HT2A receptor. Journal of Histochemistry and Cytochemistry 46 (1998) 811-824
55. Yamauchi M., Miyara T., Matsushima T., and Imanishi T. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Research 1067 (2006) 164-169
56. Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., Dotoli D., and Smeraldi E. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biological Psychiatry 50 (2001) 323-330